35 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2 more records may belong here and await a decision; they are not counted.
The next term ends in Feb 2030. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
1
Ending by 2030
Feb 2030
Next term end
14
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Sep 2038 · High confidence
Also notable
Ends Jun 2034 · High confidence
Also notable
Ends Oct 2035 · High confidence
A2-73 as a Therapeutic for Insomnia, Anxiety, and Agitation
US 11,337,953
Cited by 4 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2038.
ANAVEX2-73 and Certain Anticholinesterase Inhibitors Composition and Method for Neuroprotection
US 9,750,746
Granted 2017 and renewed at every maintenance window due so far. Protection runs to 2034.
A 19-144, A2-73 and Certain Anticholinesterase Inhibitor Compositions and Method for Anti-Seizure Therapy
US 10,441,563
A family of 6 related applications built on the 2019 grant. Protection runs to 2035.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 4, 2027The maintenance fee for A19-144, A2-73 and Certain Anticholinesterase Inhibitor Compositions and Method for Anti-Seizure Therapy (US 11,690,821) comes due Jan 4, 2027. Unpaid by Jul 6, 2027, it lapses early.
- 1 fee due Mar 17, 2027The maintenance fee for CRYSTAL FORMS OF tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, PROCESSES OF MAKING SUCH FORMS, AND THEIR PHARMACEUTICAL COMPOSITIONS (US 10,413,519) comes due Mar 17, 2027. Unpaid by Sep 17, 2027, it lapses early.
- 2 fees due Apr 1 to 15, 2027 · next Apr 1
- 2 fees due May 10 to 14, 2027 · next May 10
- 2 fees due Jun 12 to 17, 2027 · next Jun 12
- 1 fee due Aug 13, 2027The maintenance fee for Analgesic therapeutic and method, 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof (US 11,896,590) comes due Aug 13, 2027. Unpaid by Feb 14, 2028, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 16, 2026
What they patent
The 5 largest of its 14 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,180,106 | Sigma Receptors Ligands with Anti-Apoptotic And/Or Pro-Apoptotic Properties, Over Cellular Mechanisms, Exhibiting Prototypical Cytoprotective and Also Anti-Cancer Activity In force · High confidence | In force | High confidence | |
| US 9,750,746 | ANAVEX2-73 and Certain Anticholinesterase Inhibitors Composition and Method for Neuroprotection In force · High confidence | In force | High confidence | |
| US 10,441,563 | A 19-144, A2-73 and Certain Anticholinesterase Inhibitor Compositions and Method for Anti-Seizure Therapy In force · High confidence | In force | High confidence | |
| US 10,813,907 | A19-144, A2-73 and Certain Anticholinesterase Inhibitor Compositions and Method for Anti-Seizure Therapy In force · High confidence | In force | High confidence | |
| US 11,690,821 | A19-144, A2-73 and Certain Anticholinesterase Inhibitor Compositions and Method for Anti-Seizure Therapy In force · High confidence | In force | High confidence | |
| US 12,594,256 | A19-144, A2-73 and Certain Anticholinesterase Inhibitor Compositions and Method for Anti-Seizure Therapy In force · High confidence | In force | High confidence | |
| US 10,413,519 | CRYSTAL FORMS OF tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, PROCESSES OF MAKING SUCH FORMS, AND THEIR PHARMACEUTICAL COMPOSITIONS In force · High confidence | In force | High confidence | |
| US 10,966,952 | Crystal Forms of TETRAHYDRO-N,N-DIMETHYL-2,2-Diphenyl-3-Furanmethanamine Hydrochloride, Processes of Making Such Forms, and Their Pharmaceutical Compositions In force · High confidence | In force | High confidence | |
| US 11,617,734 | Enantiomers of A2-73, Analogues, and Sigma Agonist Activity In force · High confidence | In force | High confidence | |
| US 12,208,079 | Enantiomers of A2-73, Analogues, and Sigma Agonist Activity In force · High confidence | In force | High confidence |
Also on record, not counted in the 35: 15 applications pending · 2 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.